Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
life sciences
national blog main
san francisco blog main
3
×
clinical trials
national top stories
abbvie
allergan
alzheimer's disease
astellas pharma
atlas venture
audentes therapeutics
avapritinib
avidity biosciences
bluebird bio
blueprint medicines
cancer
cancer drugs
capmatinib
crispr
cynthia collins
deals
duchenne muscular dystrophy
dyne therapeutics
editas medicine
eli lilly
europe blog main
europe top stories
facioscapulohumeral muscular dystrophy
gastrointestinal stromal tumors
gene editing
gene therapy
genentech
indiana blog main
indiana top stories
joshua brumm
kaleido biosciences
What
genetic
3
×
medicines
3
×
drug
experimental
abbvie
address
ago
alliance
approval
approves
biotech
biotechs
blueprint
cancer
carries
certain
considering
data
designed
diseases
dyne
early
editas
editing
exits
expected
eyes
fda
gene
having
humans
ipo
ipos
latest
long
muscle
pact
partnership
pass
pruning
Language
unset
Current search:
genetic
×
medicines
×
" san francisco blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact